Should older adults stop taking statins? What a new study found

For millions of older adults, a daily statin pill is a decades-long routine — started sometime in middle age to lower cholesterol and reduce the risk of a heart attack or stroke, and rarely questioned since. A new study is now adding weight to a question doctors have increasingly been asking about the oldest patients: does everyone need to keep taking it forever? Researchers found that stopping statins in people over 75 who were at low risk for heart disease did not increase deaths.

Statins are among the most widely prescribed drugs in the world, credited with meaningfully cutting heart attack and stroke rates since they came into wide use decades ago. Because the large clinical trials that established their benefits mostly enrolled middle-aged adults, however, there has long been a gap in the evidence for people well into their seventies, eighties and beyond — a population where statins are nonetheless prescribed just as routinely, often without ever being reassessed.

The new research focuses specifically on primary prevention: people over 75 who had never had a heart attack, stroke or other cardiovascular event, and who were taking a statin to lower their baseline risk rather than to prevent a repeat event. That's an important distinction, because it says nothing about statins prescribed after someone has already had a heart attack or stroke — so-called secondary prevention, where the evidence for staying on the medication for life remains strong and unchanged.

Among the low-risk, primary-prevention group the study tracked, participants who stopped taking their statin did not die at a higher rate than those who continued. That finding matters because it runs counter to a common assumption that any interruption in statin therapy carries meaningful risk, regardless of a patient's individual circumstances or how the drug was originally prescribed.

The question of whether to keep prescribing statins indefinitely to very old patients has been building for years, driven by the practical realities of aging. Older adults are more likely to be on multiple medications at once, raising the risk of drug interactions and side effects, and statins in particular have been linked by some patients to muscle aches and weakness that can affect mobility and quality of life. As people move further past 75, other causes of death also become more likely relative to cardiovascular disease, which can shift the balance of a drug's benefits against its burdens.

Deprescribing, the deliberate process of stopping or reducing medications that may no longer provide a clear benefit, has become its own area of geriatric research precisely because of that shifting balance. Advocates argue that treatment decisions made in someone's fifties or sixties shouldn't automatically carry forward unexamined into their eighties and nineties, particularly for drugs taken to prevent a first event that, statistically, becomes progressively less likely to be the deciding factor in how long someone lives.

The study's authors and outside researchers are careful to draw a firm line around who the findings apply to. People with a history of heart attack, stroke, diabetes, familial high cholesterol or other elevated-risk conditions were not the focus of this research, and cardiologists continue to recommend that those patients stay on statins regardless of age, since the evidence for benefit in secondary prevention remains robust across age groups.

Geriatricians and cardiologists who work with older patients have welcomed the new data as a step toward more individualized care, rather than a blanket rule in either direction. The goal, several say, isn't to encourage every older patient to stop their statin, but to give doctors and patients solid evidence to draw on when deciding, case by case, whether a medication prescribed years or decades earlier still makes sense given a person's current health, life expectancy and priorities.

For patients, the practical message from the research is not to stop taking a statin unilaterally. Any decision to discontinue the drug should be made together with a doctor, who can weigh a patient's full cardiovascular risk profile, other health conditions and personal preferences — factors the study's low-risk primary-prevention population doesn't necessarily reflect for every individual reader.

The findings add to a broader push in geriatric medicine to match the intensity of treatment to the actual benefit it's likely to provide as people age, rather than defaulting to lifelong continuation of medications started decades earlier. As the global population of adults over 75 continues to grow, researchers say more studies like this one — testing long-held prescribing assumptions specifically in the oldest patients — are likely to follow.